Polymerases have a structurally highly conserved negatively charged amino acid motif that is strictly required for Mg 2+ cation-dependent catalytic incorporation of (d)NTP nucleotides into nucleic acids. Based on these characteristics, a nucleoside monophosphonate scaffold, α-carboxy nucleoside phosphonate (α-CNP), was designed that is recognized by a variety of polymerases. Kinetic, biochemical, and crystallographic studies with HIV-1 reverse transcriptase revealed that α-CNPs mimic the dNTP binding through a carboxylate oxygen, two phosphonate oxygens, and base-pairing with the template. In particular, the carboxyl oxygen of the α-CNP acts as the potential equivalent of the α-phosphate oxygen of dNTPs and two oxygens of the phosphonate group of the α-CNP chelate Mg 2+ , mimicking the chelation by the β-and γ-phosphate oxygens of dNTPs. α-CNPs (i) do not require metabolic activation (phosphorylation), (ii) bind directly to the substrate-binding site, (iii) chelate one of the two active site Mg 2+ ions, and (iv) reversibly inhibit the polymerase catalytic activity without being incorporated into nucleic acids. In addition, α-CNPs were also found to selectively interact with regulatory (i.e., allosteric) Mg 2+ -dNTP-binding sites of nucleos(t)ide-metabolizing enzymes susceptible to metabolic regulation. α-CNPs represent an entirely novel and broad technological platform for the development of specific substrate active-or regulatory-site inhibitors with therapeutic potential. The polymerization of nucleotides by Escherichia coli DNA polymerase I represents a general model for catalytic action of nucleic acid polymerases (SI Appendix, Fig. S1 ) (1, 2). According to this model, there is a universal role for the Mg 2+ cation to interact with three phosphate oxygens of dNTP. The highly conserved consensus motifs in every polymerase active site consist of either aspartate or glutamate residues that chelate Mg 2+ through three additional coordination bonds during polymerization (2, 3). The crucial role of the metal cofactor and structurally conserved active site architecture in polymerases has also been demonstrated by validating Mg 2+ as a target for the design of antiviral drugs, not only against HIV RT but also, among others, against HIV integrase, HIV ribonuclease H (RNase H), and influenza-encoded endonuclease (4, 5). Hence, it should be feasible to design a universal but simplified (d)NTP mimic that binds efficiently to a wide variety of DNA/RNA polymerases.
Polymerases have a structurally highly conserved negatively charged amino acid motif that is strictly required for Mg 2+ cation-dependent catalytic incorporation of (d)NTP nucleotides into nucleic acids. Based on these characteristics, a nucleoside monophosphonate scaffold, α-carboxy nucleoside phosphonate (α-CNP), was designed that is recognized by a variety of polymerases. Kinetic, biochemical, and crystallographic studies with HIV-1 reverse transcriptase revealed that α-CNPs mimic the dNTP binding through a carboxylate oxygen, two phosphonate oxygens, and base-pairing with the template. In particular, the carboxyl oxygen of the α-CNP acts as the potential equivalent of the α-phosphate oxygen of dNTPs and two oxygens of the phosphonate group of the α-CNP chelate Mg 2+ , mimicking the chelation by the β-and γ-phosphate oxygens of dNTPs. α-CNPs (i) do not require metabolic activation (phosphorylation), (ii) bind directly to the substrate-binding site, (iii) chelate one of the two active site Mg 2+ ions, and (iv) reversibly inhibit the polymerase catalytic activity without being incorporated into nucleic acids. In addition, α-CNPs were also found to selectively interact with regulatory (i.e., allosteric) Mg 2+ -dNTP-binding sites of nucleos(t)ide-metabolizing enzymes susceptible to metabolic regulation. α-CNPs represent an entirely novel and broad technological platform for the development of specific substrate active-or regulatory-site inhibitors with therapeutic potential. The polymerization of nucleotides by Escherichia coli DNA polymerase I represents a general model for catalytic action of nucleic acid polymerases (SI Appendix, Fig. S1 ) (1, 2) . According to this model, there is a universal role for the Mg 2+ cation to interact with three phosphate oxygens of dNTP. The highly conserved consensus motifs in every polymerase active site consist of either aspartate or glutamate residues that chelate Mg 2+ through three additional coordination bonds during polymerization (2, 3) . The crucial role of the metal cofactor and structurally conserved active site architecture in polymerases has also been demonstrated by validating Mg 2+ as a target for the design of antiviral drugs, not only against HIV RT but also, among others, against HIV integrase, HIV ribonuclease H (RNase H), and influenza-encoded endonuclease (4, 5) . Hence, it should be feasible to design a universal but simplified (d)NTP mimic that binds efficiently to a wide variety of DNA/RNA polymerases.
It was hypothesized that a universal nucleoside triphosphate mimic should contain three major indispensable entities: (i) a nucleobase part (i.e., to achieve optimal Watson-Crick basepairing with the template overhang), (ii) a replacement of the triphosphate moiety that should enable efficient Mg 2+ -directed coordination, and (iii) a variable linker between the nucleobase and the modified triphosphate to mimic the pentose entity present in natural (d)NTPs. For the triphosphate part, we chose an α-carboxy phosphonate entity that is chemically stable in physiological media and cannot be released from the triphosphate mimic by cellular (hydrolytic) enzymes. It was assumed that the carboxylate in the phosphonate moiety might help to coordinate Mg 2+ . The phosphonate moiety, such as in the clinically used tenofovir (6), was chosen (instead of a phosphoester) to provide additional metal chelation affinity and to confer stability by preventing enzymatic hydrolysis. Given the fact that (2-deoxy)ribose, the most logical linker entity between nucleobase and phosphonate, could not be synthetically incorporated due to the intrinsic lability of the ether oxygen bridge that links the pentose to the phosphonate, a cyclopentyl ring was initially introduced as the
Significance
The polymerization of nucleotides by DNA polymerases occurs through a common mechanism based on similar highly conserved amino acid motifs and the universal role of the coordination of Mg 2+ by three dNTP phosphate oxygens. Based on these universal principles, we aimed at designing a dNTP mimic that could interact with a broad variety of DNA polymerases and should consist of three major indispensable entities: a nucleobase for Watson-Crick base-pairing, an enzymatically and chemically stable triphosphate replacement that can efficiently coordinate the Mg 2+ cation, and a variable linker moiety between the nucleobase and the modified phosphate. The resulting α-carboxy nucleoside phosphonates (α-CNPs) were structurally, kinetically, and biochemically investigated, and the novel dNTP mimics were successfully validated in several DNA polymerase models.
linker moiety, as has been done before for the HIV-1 nucleoside RT inhibitor (NRTI) carbovir (7) .
To investigate and validate the design of a universal (d)NTP mimic, we chose the well-characterized HIV-1 RT as a preferred model system, as a variety of kinetic, biochemical, and structural tools are available and well-established to study this enzyme. Table S1 ). Pronounced enzyme inhibition was found only when the α-CNPs contained the same natural nucleobase as the competing radiolabeled dNTP substrate. The template/primer-specific inhibition of HIV-1 RT by α-CNPs strongly suggests that α-CNPs compete with the natural dNTP substrate for binding to the enzyme. This conclusion was further substantiated in more detailed kinetic experiments using different homopolymeric template/primers and their corresponding dNTP substrates, as evident from the substrate versus velocity plots in SI Appendix, Fig. S2A and the kinetic calculations using the mixed model inhibition of GraphPad (SI Appendix, Table S2 ). These plots also revealed mixed-type (close-to-uncompetitive) inhibition of RT against the template/primer by T-α-CNP (SI Appendix, Fig. S2B ), which indicates that binding of template/ primer to HIV-1 RT is required before efficient binding of the α-CNP to the enzyme. Although structurally distinct, the α-CNP inhibition kinetics (SI Appendix, Fig. S2 A and B) resembled not only those of the well-known DNA chain-terminating NRTI AZT-TP (SI Appendix, Fig. S2 C and D) (11) but also those of the nucleotide-competing RT inhibitor (NcRTI) INDOPY-1 (SI Appendix, Fig. S2 E and F) . INDOPY-1 is the prototype compound of a well-defined class of nonnucleoside indolopyridinones that interact-like NRTIs-with the substrate active site of HIV RT in a competitive manner with the natural dNTP substrates (12) .
Results
L-enantiomeric α-CNPs were also found to be inhibitory against a broad variety of other lentiviral RTs (Table 1) , mostly, like nucleo(s)(t)ide RT inhibitors (N(t)RTIs), within the same order of magnitude. Given the highly conserved structural motifs (i.e., Asp/Glu residues) and functional coordination properties of Mg 2+ in the polymerase active sites, we hypothesized that α-CNPs that function as (d)NTP mimics should also inhibit other polymerases. The interactions of the T-, C-, and A-α-CNP derivatives with several herpetic DNA polymerases were therefore investigated. As evident from Table 1 , α-CNPs indeed interact with the herpetic DNA polymerases and also, but less strongly, with the cellular DNA polymerases α and β. The inhibitory activities of the triphosphate of the retroviral AZT (zidovudine), the herpetic (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU, brivudine), and the pyrophosphate analog phosphonoformic acid (PFA, foscarnet) inhibitors have been included as controls (Table 1) . AZT-TP proved 4-to 50-fold more inhibitory to the lentiviral RTs, BVDU-TP was 10-to 100-fold more inhibitory to the herpetic DNA polymerases, whereas PFA was equally inhibitory against HIV-1 RT and FIV RT, 30-fold more inhibitory against HIV-2 RT and SIV RT, four-to eightfold more inhibitory to HCMV and HSV-1 DNA polymerase, and 200-fold more inhibitory to VZV DNA polymerase than T-α-CNP. Instead, the reference compounds BVDU-TP and PFA were markedly more inhibitory against the cellular DNA polymerase α than the α-CNPs (Table 1) .
Although the affinity of the α-CNPs was clearly superior for HIV-1 RT, followed by herpetic DNA polymerases, and lowest for the cellular DNA polymerases, it should be taken into account that the pentose mimicking (cyclopentyl) part of the α-CNP is more suited to inhibit RTs (mimicking a 2′,3′-dideoxyribose) and least appropriate for inhibiting the cellular DNA polymerases α and β, which prefer an intact 2-deoxyribose. Taking this in mind, an acyclic α-CNP has been designed (SI Appendix, Fig. S3 ) containing an aliphatic butenyl bridge. Such an aliphatic (acyclic) moiety has previously been shown to generate compounds with antiherpetic activity (13) . This modified α-CNP indeed demonstrated a pronounced inhibition of all three herpetic DNA polymerases, and its inhibitory activity was by far superior (selective) for these viral enzymes compared with HIV RT and DNA polymerase α (Table 2) . Thus, marked selectivity and preferential interaction with well-defined polymerases can be obtained by fine-tuning the α-CNP scaffold to the particular target (polymerase) enzymes.
Biochemical Studies. To provide more detailed mechanistic insight, inhibition of DNA synthesis was studied in gel-based assays. Dose-response experiments were performed with heteropolymeric DNA/DNA substrates that offer multiple binding sites for inhibitor and natural substrates (Fig. 1A and SI Appendix, Fig. S4 ). T-, C-, or A-containing α-CNPs (pure L-enantiomers) show inhibition patterns that reflect the different nature of the nucleobase. Inhibition of DNA synthesis is always observed at a single site before the predicted location at which the competitive inhibitor interacts with its natural template nucleobase counterpart (Fig. 1A) . This also demonstrates that α-CNPs are not incorporated into the growing DNA chain, which would have changed the primer migration. Time-course experiments at a fixed concentration of α-CNPs revealed that inhibition is reversible (SI Appendix, Fig. S4 ). In the presence of the respective T-, C-, or A-containing α-CNPs, the formation of the full-length product was significantly delayed, in favor of multiple abortive products. The short reaction products disappeared as a function of time, which is indicative of enzyme pausing and reversible inhibition. Hence, the mechanism of α-CNP inhibition does not involve DNA chain termination as demonstrated for N(t)RTIs (7, 11) . Rather, the RT inhibition by α-CNPs is reminiscent of the mechanism of action described for INDOPY-1 (12) and involves reversible competition at or in close proximity to the dNTP-binding site. Next, it was investigated if α-CNPs are capable of forming stable ternary complexes, as demonstrated for nucleotides and INDOPY-1. Complex formation was monitored with increasing concentrations of C-α-CNP against four different template/primer combinations that contained either T, A, G, or C in the template overhang at the nucleotide-binding site (Fig. 1B) . Stable, heparin-resistant ternary complexes were only seen with a templating guanine base, which is strongly indicative for specific WatsonCrick base-pairing. These findings contrast with the NcRTI INDOPY-1, which was able to form a stable ternary complex irrespective of the nature of the templating nucleotide base (SI Appendix, Fig. S5) .
Finally, the influence of the inhibitor on the precise position of HIV-1 RT on its template/primer was studied through Fe 2+ -mediated, high-resolution footprinting. Upon binding of Fe 2+ ions to the RNase H domain of HIV-1 RT, the template is cut in a site-specific manner that enables the distinction between pre-and posttranslocational conformations of the RT-template/ primer complex (14) . The enzyme shuttles between the two positions and accommodates either the 3′ end of the primer (pretranslocation) or the nucleotide substrate (posttranslocation) at the active site. Increasing concentrations of C-α-CNP shift this dynamic equilibrium toward posttranslocation (SI Appendix, Fig. S6 ). Thus, α-CNPs, like natural dNTP substrates and like INDOPY-1 (12), bind to, and trap, the posttranslocational RT conformation.
Structural Studies. The crystal structure of the HIV-1 RT/dsDNA/ T-α-CNP ternary complex was determined at 2.9 Å resolution ( Fig. 2A and SI Appendix, Fig. S7 and Table S3 ). In agreement with the kinetic data, the structure revealed the binding of T-α-CNP at the dNTP-binding site (N site) of an RT/dsDNA posttranslocational complex. Mimicking a dNTP, (i) the thymine part of T-α-CNP is base-paired with the template adenine base overhang; (ii) the cyclopentyl ring interacts with Y115, Q151, and M184 from three sides in a manner analogous to the interactions of the 2′-deoxyribose ring of a dNTP; and (iii) the carboxymethylphosphonate part chelates a Mg 2+ ion (metal B) at the polymerase active site. In general, binding of T-α-CNP is analogous to a dNTP and distinct from a pyrophosphate (or foscarnet), which binds the pretranslocated RT/nucleic acid complex at a location that can be occupied by the pyrophosphate (PPi) leaving group (15) .
The most striking feature is the unusual and unexpected mode of chelation of the α-carboxy-phosphonate at the polymerase active site. Two oxygens of the phosphonate group of α-CNP chelate metal B, replacing the chelation by β-and γ-phosphate oxygens of a dNTP. A carboxyl oxygen of α-CNP is the positional equivalent of the α-phosphate oxygen of dNTP that chelates both metals A and B. The positions and orientations of the catalytic residues (D110, D185, and D186) in the T-α-CNP complex superimpose well with those in RT/nucleic acid/dNTP (or analog) ternary complexes (SI Appendix, Fig. S7 ). However, like in most of the crystal structures of RT/dsDNA/dNTP (or analog) complexes (16), electron density for metal A is not observed. Thereby, the α-CNP in the current structure maintains a complete octahedral coordination environment for the catalytic metal ion B and satisfies the geometrical and chemical requirements to involve the metal ion A (Fig. 2B) . Unlike a triphosphate moiety, the chelated α-carboxy-phosphonate group does not contain a phosphodiester bond for hydrolysis by RT, and thereby, α-CNP forms a nonproductive ternary complex state with RT, leading to inhibition. This fundamental and indispensable role of the Mg 2+ -coordinating capacity of the three oxygens in the α-CNP is further confirmed by the demonstration that modifying one of these three oxygen atoms in the α-CNP with a methyl group such as in the mono-and trimethylated T-α-CNP (SI Appendix, Figs. S3 and S7) completely obliterated the interaction of the compounds with HIV RT (IC 50 > 100 μM). Thus, α-CNPs are entirely novel, efficient, and simplified mimics of the natural dNTP substrates that inhibit HIV-1 RT as competitive inhibitors.
Sensitivity Against HIV-1 RT with Known Resistance-Conferring
Mutations. Like NRTIs, α-CNPs are sensitive to RT mutations adjacent to the pentose/cyclopentyl ring. The mutation M184V confers 1.7-to 16-fold resistance to α-CNPs depending on the nature of the nucleobase in the α-CNP (SI Appendix, Table S4 ). The M184V mutation has also been reported to confer resistance of HIV-1 RT to INDOPY-1 (17) , and earlier also to the L-nucleoside inhibitors lamivudine (3TC) and emtricitabine (FTC) (18) . This resistance was shown to be due to steric hindrance of the L-sugar ring by the 184-valine side chain (19) . The crystal structure suggests a similar mechanism of resistance for α-CNPs by the M184V mutation in HIV-1 RT. Another mutation, Y115F, demonstrated diminished inhibitory activity of the NcRTI INDOPY-1 against HIV-1 RT (17), however the mutation had no noticeable impact on the inhibitory activity of the C-and A-α-CNPs (SI Appendix, Table S4 ). The decreased inhibitory activity of INDOPY-1 against mutant Y115F HIV-1 RT has been earlier ascribed to the increased binding efficiency of the natural dNTP (but not INDOPY-1) to the mutant enzyme (16) . These findings strongly suggest that the affinity of RT for α-CNPs is similarly increased in the mutant RT enzyme as observed for the dNTPs. The sensitivity data obtained for the Y115F and M184V RT mutants confirm again that α-CNPs act as novel dNTP mimics in the substrate active site of HIV-1 RT that is lined by both Y115 and M184.
Interference of α-CNPs with dNTP-Driven Enzyme Regulation. For a wide variety of enzymes, the activity is controlled by their reaction products or metabolic end-products through feedback or allosteric regulation. -bound dNTP and ATP; and allosteric activation of dNTP hydrolase by (d)GTP (20) (21) (22) (23) (24) . Therefore, the potential of α-CNPs to act as dNTP mimics in such enzymatic regulation processes was also investigated. Interestingly, T-α-CNP, but not C-and A-α-CNPs, dosedependently inhibited TK-2-catalyzed dThd phosphorylation (Fig. 3) . The natural metabolic end-product inhibitor Mg 2+ -dTTP suppressed the enzyme at a ∼20-fold lower concentration (IC 50 , ∼2.5 μM). The herpesvirus TKs were less sensitive to the inhibitory action of dTTP and α-CNPs. In contrast with TK-2, TK-1 was not inhibited by T-α-CNP (IC 50 , >200 μM), although Mg 2+ -dTTP showed a pronounced feedback inhibition of the enzyme (IC 50 , 1.5 μM) (Fig. 3 and SI Appendix, Fig. S8 ). T-α-CNP behaved as a noncompetitive inhibitor of TK-2 in the presence of dThd and thus might interact at a regulatory binding site (SI Appendix, Fig.  S8 and Table S5 ) (25) . Our kinetic findings are indeed strongly suggestive for specific recognition of T-α-CNP by TK-2. The complete lack of inhibitory activity of T-α-CNP against TK-1 may be related to the fact that TK-1 belongs to the type I class of TKs and structurally differs from type II class TK-2 and herpetic TKs (26) . It has been demonstrated that the nucleobase of the natural allosteric TK inhibitor dTTP is hydrogen-bonded to main-chain atoms in TK-1, in contrast to other nucleoside kinases where specific interaction occurs with amino acid side chains (26) .
The C-α-CNP derivative was found to interact with the stimulatory allosteric Mg 2+ -dCTP binding site on dCMPD. In the absence of dCTP, dCMPD activity could be hardly observed. Instead, in the presence of 250 μM dCTP, a pronounced deamination of dCMP was found that linearly proceeded up to a dCMP concentration of 100 μM (SI Appendix, Fig. S8 ). Unlike dCTP, C-α-CNP did not stimulate dCMPD activity per se but instead markedly inhibited the Mg 2+ -dCTP-driven enzyme activity (SI Appendix, Fig. S8 ). It was also ascertained that C-α-CNP did not act as a substrate for dCMPD. The dose-dependent inhibition profiles of C-α-CNP against dCMPD in the presence of a fixed dCTP (250 μM) concentration were remarkably similar at varying dCMP concentrations. Thus, our findings indicate that C-α-CNP selectively interacts with the allosteric stimulatory (Mg 2+ -dCTP) binding site of dCMPD by antagonizing the dCTP stimulatory effect without being able to stimulate enzyme activity per se.
The interference of α-CNPs with allosteric inhibitory or stimulatory activities of (d)NTP-binding proteins may have therapeutic potential, as it has been previously demonstrated that dCTP not only stimulates the conversion of dCMP into dUMP (21) but also the conversion of the anticancer cytosar (araCMP) and gemcitabine (dFdCMP) metabolites to their inactive uridylate derivatives (27, 28) . α-CNP may prevent such inactivation by its antagonistic potential.
Studies on Intact Cells, Crude Cell Extracts, and Purified Enzymes. The T-α-CNP, C-α-CNP, and A-α-CNP derivatives were exposed to exponentially growing human CD4 + T lymphocyte CEM and cervix carcinoma HeLa cell cultures but also confluent (monolayer) human lung fibroblast HEL and HeLa cell cultures for 3-4 d. None of the compounds were cytostatic or cytotoxic at 200 μM. They were also evaluated for potential anti-HIV-1 and anti-HIV-2 activity in human CD4
+ T-lymphocyte CEM cell cultures and for anti-HSV-1 and anti-HSV-2 activity in human embryonic lung HEL fibroblasts, but found inactive at the highest concentration tested (200 μM).
To reveal whether cellular enzymes may further metabolize (i.e., phosphorylate) the α-CNPs, CEM cell extracts but also purified recombinant UMP/CMP kinase and NDP kinase were administered to 100 μM T-α-CNP, U-α-CNP, C-α-CNP, or A-α-CNP in the presence of ATP and incubated for up to 6 h at 37°C. They were not able to convert the compounds to a phosphorylated derivative, as inspected by HPLC analysis. Instead, 100 μM CMP or UMP was fully converted to cytidine diphosphate (CDP) or UDP by UMP/CMP kinase, and 100 μM thymidine diphosphate (dTDP), CDP, or adenosine diphosphate (ADP) was efficiently converted to their triphosphate derivatives by NDP kinase within 1 h of incubation.
Discussion
Kinetic, biochemical, and structural studies revealed that α-CNPs represent a novel synthetic scaffold and technological platform for designing specific tailor-made polymerase inhibitors that make use of both the highly conserved architecture and amino acid motifs in nucleic acid polymerases and the central role that hexa-coordinated Mg 2+ plays in the catalytic activity of the polymerases. The α-CNPs function as efficient (d)NTP mimics in which one of the carboxylate oxygens and two phosphonate oxygens are of crucial importance in coordinating Mg 2+ ions. The α-CNPs are the first (d)NTP mimics that structurally consist of a simple nucleoside monophosphonate scaffold not requiring further metabolic conversion (phosphorylation) for interaction with the target enzymes. Their mechanism of action, structural interaction with HIV-1 RT, and kinetic/biochemical properties are unique and differ from all known polymerase inhibitor classes of compounds (SI Appendix, Table S6 ).
The demonstration that α-CNPs inhibit different polymerases and enzymes that contain regulatory dNTP-binding sites is unique from a fundamental viewpoint and may also have important translational and chemotherapeutic implications. The α-CNPs can be used to study allosteric (dNTP) site binding effects leading to selective antagonistic inhibition or activation of enzyme activity. It has indeed been shown earlier that thymidine kinase activity can be modulated by 5′-amino-dThd (5′-AdThd), as the natural dTTP does, affecting the cytotoxicity and metabolism of various dThd analogs used in the clinic as antineoplastic agents (29) . 5′-AdThd was shown to antagonize dTTP feedback inhibition of TK and therefore to stimulate the anabolism of the anticancer drug 5-FdUrd (30) . Thus, the use of compounds capable of antagonizing feedback inhibition of nucleoside analog activation (phosphorylation) may provide new means of increasing the efficacy of cytotoxic (anticancer) nucleoside analogs.
The α-CNPs might also have the intrinsic ability to target a wide variety of other (d)NTP-binding proteins, potentially also including G protein-coupled receptors (31), providing new opportunities in drug discovery. G protein-coupled receptors include a most diverse group of membrane receptors responsible for conducting many physiological processes through signal transduction, including intercellular communication, neuronal transmission, and hormonal signaling (32) . They are also involved in a variety of pathological processes (31, 33) and are currently targets for at least one third of the pharmaceutical drug market (31). The design of α-CNPs may also represent a technological tool for facilitating biochemical and structural studies of (d)NTPbinding proteins in the presence of α-CNPs as nonhydrolysable (d)NTP mimics. In fact, the nonhydrolysable ATP mimic adenosine 5′-(β,γ-methylene)triphosphate has been demonstrated to be instrumental for an improved crystallography of proteins that use ATP as one of their ligands and to obtain mechanistic insights in the role of ATP in enzyme interaction and catalysis (34, 35) . Therefore, α-CNPs should be further investigated for their interaction with (d)ATP-, (d)CTP-, or (d)TTP-binding proteins from a crystallographic and mechanistic viewpoint.
None of the α-CNPs have shown so far any significant cytostatic or cytotoxic activity in cell culture at concentrations as high as 100 μM. However, one of the reasons may be the poor, if any, efficient cellular uptake of the α-CNPs due to their highly charged nature. Cellular uptake should therefore be enhanced by designing lipophilic prodrugs of the α-CNPs neutralizing the phosphonate charge, a strategy that is applied in the clinically used drugs adefovir dipivoxil (Hepsera), tenofovir disoproxil (Viread), and tenofovir alafenamide (36, 37) . These attempts are currently ongoing in our laboratories. Although it should be recognized that α-CNP selectivity will be a challenge in terms of target specificity, structural optimization (finetuning) in the nucleobase, α-carboxy phosphonate, and/or the linker (pentose) portions of the molecules may address this issue, as already demonstrated for the acyclic α-CNPs that are shown to have a shifted selectivity from HIV-1 RT to herpetic DNA polymerases.
Methods
Detailed descriptions of the experimental set-ups and compound characterization are provided in SI Appendix, SI Methods. Inhibition of RTs by the α-CNPs was evaluated using the respective homopolymeric template/primers poly rA.dT, poly rI.dC, and poly rU.dA and their appropriate corresponding radiolabeled dNTP substrates (Table 1 ) or in the presence of T50A DNA template/5′-radiolabeled PI DNA primer and a fixed dNTP concentration (Fig.  1) . The herpetic DNA polymerases and the cellular DNA polymerases used gapped calf thymus DNA as the template (Table 1) , except for VZV DNA polymerase, where poly dA.poly dT was used. The X-ray diffraction data were obtained for the HIV-1 RT/dsDNA/T-α-CNP ternary complex that contained a template adenine base overhang to allow base-pairing with T-α-CNP (Fig. 2) . Allosteric inhibition of viral and cellular thymidine kinases and cellular dCMPD by α-CNPs was performed in the presence of the natural substrates (dThd and dCMP, respectively) and dCTP (for the dCMPD assay) and analyzed by anion exchange HPLC (Fig. 3) .
